Dr Stuart Sims

Industry Partnerships and Commercialisation Executive, Natural Sciences

Dr Stuart Sims is Industry Partnerships and Commercialisation Executive in the Faculty of Natural Sciences at Imperial College London

Stuart's portfolio

Novel treatment for Huntington’s Disease using zinc finger gene therapy

Novel treatment for Huntington’s Disease using zinc finger gene therapy

A novel gene therapy for Huntington’s Disease that leverage zinc finger protein technology. Find out more

Aptamer-based multiplex screening platform

Aptamer-based multiplex screening platform

A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier. Find out more

DEP Trapping Using Metallised Nanopipettes

DEP Trapping Using Metallised Nanopipettes

This invention enables efficient single molecule nanopore sensing at femtomolar concentrations using dielectrophoretic trapping by combining nanopore sensing and dielectrophoresis (DEP). Find out more

Nanotweezers for single-cell biopsy

Nanotweezers for single-cell biopsy

Inexpensive, easy to fabricate and use, dielectrophoretic nanotweezers for non-destructive subcellular concentration (trapping) and extraction of biomolecules. Find out more

Zinc finger therapy for Amyotrophic lateral sclerosis (ALS) and Frontotemporal dementia (FTD)

Zinc finger therapy for Amyotrophic lateral sclerosis (ALS) and Frontotemporal dementia (FTD)

A zinc finger to target both the ALS and FTD therapeutically Find out more

Zinc finger therapy for Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)

Zinc finger therapy for Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)

A zinc finger (zf) to target the FXTAS mutation therapeutically Find out more

Active delivery of Zinc Fingers for in vivo enhancement of gene regulation

Active delivery of Zinc Fingers for in vivo enhancement of gene regulation

A universal method to enhance control of gene expression in vivo with artificial gene-regulatory transcription factors (TFs). Find out more

Novel vortex laser

Novel vortex laser

A high-power and high-efficiency new methodology for laser vortex creation that enables new devices and applications with vortex spatial format. Find out more

Novel inhibitor of neuropathic pain

Novel inhibitor of neuropathic pain

This novel neutralising antibody-based approach offers an innovative and valuable therapeutic strategy for patients with neuropathic pain. Find out more

Human monoclonal antibodies to COVID-19

Human monoclonal antibodies to COVID-19

A suite of broad neutralising monoclonal antibodies (bnMABs) isolated to be used for treatment of coronaviruses with a focus on SARS-CoV-2 (2019-nCoV). Find out more

First-in-class drug candidate for treatment of multiple myeloma and Diffuse Large B Cell Lymphoma

First-in-class drug candidate for treatment of multiple myeloma and Diffuse Large B Cell Lymphoma

DTP3 is a first-in-class GADD45β/MKK7 inhibitor targeting the NF-κB pathway Find out more

High-resolution transcription start site mapping using nanogram-levels of total RNA immunoprecipitation (SLIC-CAGE)

High-resolution transcription start site mapping using nanogram-levels of total RNA immunoprecipitation (SLIC-CAGE)

A novel development of the cap-trapper CAGE protocol which can generate complex high-quality libraries for as little as 5-10 nanograms of cellular RNA. Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...